WO2021246388A1 - 癒着防止剤及びそれを用いた癒着防止方法 - Google Patents

癒着防止剤及びそれを用いた癒着防止方法 Download PDF

Info

Publication number
WO2021246388A1
WO2021246388A1 PCT/JP2021/020791 JP2021020791W WO2021246388A1 WO 2021246388 A1 WO2021246388 A1 WO 2021246388A1 JP 2021020791 W JP2021020791 W JP 2021020791W WO 2021246388 A1 WO2021246388 A1 WO 2021246388A1
Authority
WO
WIPO (PCT)
Prior art keywords
anionized
adhesion
group
adhesion agent
dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/020791
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
淳 大畑
拓道 山下
栞理 藤本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Factory Inc
Original Assignee
Otsuka Pharmaceutical Factory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2022528834A priority Critical patent/JP7321610B2/ja
Priority to BR112022022193A priority patent/BR112022022193A2/pt
Priority to EP21817270.8A priority patent/EP4159251A4/en
Priority to CN202180039187.4A priority patent/CN115884800A/zh
Priority to MX2022015193A priority patent/MX2022015193A/es
Priority to AU2021284433A priority patent/AU2021284433A1/en
Priority to US18/007,603 priority patent/US20230226098A1/en
Priority to KR1020227046355A priority patent/KR20230018490A/ko
Priority to CA3189526A priority patent/CA3189526A1/en
Application filed by Otsuka Pharmaceutical Factory Inc filed Critical Otsuka Pharmaceutical Factory Inc
Publication of WO2021246388A1 publication Critical patent/WO2021246388A1/ja
Priority to ZA2022/11627A priority patent/ZA202211627B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Definitions

  • the present invention relates to an adhesion-preventing agent and an adhesion-preventing method using the same.
  • Adhesion refers to the state in which the surfaces of tissues that should be separated from each other are connected or fused with fibrous tissue. Adhesives occur frequently after abdominal surgery, causing adhesive bowel obstruction, difficulty and increased risk of reoperation, decreased fertility, and chronic abdominal pain. In particular, in the case of intestinal obstruction caused by adhesions, it is a life-threatening problem, which is a serious clinical problem.
  • sheet-shaped adhesion-preventing materials As means for preventing adhesions, sheet-shaped adhesion-preventing materials (Seprafilm (registered trademark), Interseed (registered trademark)) and gel-like adhesion-preventing materials (Adspray (registered trademark)) are commercially available. All of these are applied or sprayed under the abdominal wall incision or on the injured area, and adhesions are reduced by providing a physical septum between the incision or the injured area and the adjacent organ.
  • Non-Patent Document 1 The gel-like adhesion-preventing material is one in which two liquids are mixed and sprayed around the damaged part to quickly gel and exert an adhesion-preventing effect. However, preparation of the two-liquid is complicated and the adhesion-preventing effect is Limited to the application site. The reason these existing anti-adhesive materials cannot completely prevent adhesive intestinal obstruction is that they are used only under abdominal wall incisions or injured areas where adhesions are clearly predicted.
  • Patent Document 1 describes that an adhesion-preventing effect was observed by applying a pulp-derived nanocellulose aqueous dispersion to the excised surface of the liver. Further, Patent Document 2 describes that by applying a microbial cellulose material to an injured site, tissue adhesion to the injured site can be minimized.
  • Patent Document 3 and Non-Patent Document 2 describe that a hydrogel composition composed of TEMPO oxidized cellulose nanofiber (TOCN), methyl cellulose, carboxymethyl cellulose and polyethylene glycol can be used to prevent adhesion of peritoneal tissue. It is described that the gel composition is a transparent liquid at 4 ° C., but has the property of gelling at 25 ° C. and 37 ° C. and losing fluidity.
  • TOCN TEMPO oxidized cellulose nanofiber
  • methyl cellulose methyl cellulose
  • carboxymethyl cellulose carboxymethyl cellulose
  • polyethylene glycol polyethylene glycol
  • An object of the present invention is to provide a novel anti-adhesion agent and an anti-adhesion method using the same. Further, it is an object of the present invention to provide an adhesion preventive agent capable of preventing adhesions in a wide range in the abdominal cavity as well as a damaged site or an inflamed site of a tissue or organ in which adhesion is predicted to occur, and an adhesion prevention method using the same. do.
  • an aqueous dispersion of anionized nanocellulose or anionized nanochitin can effectively prevent adhesions at an injured site or an inflamed site. I found.
  • the aqueous dispersion does not thicken near body temperature (it does not increase in viscosity and maintains fluidity), it should be widely applied not only to the injured or inflamed area but also to the abdominal cavity around it. It was also found that it was possible to prevent adhesions over a wide area in the abdominal cavity. Further studies based on such findings have led to the completion of the present invention.
  • the present invention provides an adhesion-preventing agent and an adhesion-preventing method using the same.
  • Item 1. An anti-adhesion agent comprising at least one anionized nanomaterial selected from the group consisting of anionized nanocellulose and anionized nanochitin as active ingredients.
  • Item 2. The anti-adhesion agent according to Item 1, wherein the anionized nanomaterial is anionized nanocellulose.
  • Item 3. Item 2.
  • Item 4. Item 2.
  • Item 5. Item 2. The anti-adhesion agent according to Item 1, wherein the anionized nanomaterial is an anionized nanokitin.
  • Agent. Item 8. Item 2. The anti-adhesion agent according to any one of Items 1 to 7, further comprising a liquid medium and anionized nanomaterials dispersed in the liquid medium.
  • Item 11. Item 2. The anti-adhesion agent according to any one of Items 8 to 10, wherein the anti-adhesion agent has a viscosity (37 ° C.) of 0.5 to 2000 mPa ⁇ s.
  • Item 12. Item 2. The anti-adhesion agent according to any one of Items 8 to 11, wherein the content of the anionized nanomaterial in the total solid content of the anti-adhesion agent is 25% by weight or more.
  • Item 13. Item 6.
  • the anti-adhesion agent according to any one of Items 1 to 12, which is applied to an organ or tissue in the abdominal cavity.
  • Item 14 At least one anionized nanomaterial selected from the group consisting of anionized nanocellulose and anionized nanochitin for use in preventing adhesions of organs or tissues in the abdominal cavity.
  • Item 15. Use of at least one anionized nanomaterial selected from the group consisting of anionized nanocellulose and anionized nanochitin to produce anti-adhesion agents.
  • Item 16 At least one anionized nanomaterial selected from the group consisting of anionized nanocellulose and anionized nanochitin for use as an anti-adhesion agent.
  • a method for preventing adhesions which comprises applying the anti-adhesion agent according to any one of Items 1 to 13 to an organ or tissue in the abdominal cavity.
  • Item 18 A method for producing an anti-adhesion agent, which is a step of mixing a liquid medium with at least one anionized nanomaterial selected from the group consisting of anionized nanocellulose and anionized nanochitin as active ingredients. Manufacturing method, including.
  • the anti-adhesion agent of the present invention can effectively prevent adhesion by applying an anionized nanomaterial which is an active ingredient to a site where adhesion is to be prevented.
  • the anti-adhesion agent of the present invention can be in the form of a dispersion containing the active ingredient (particularly, an aqueous dispersion). Since the dispersion has low viscosity and moderate fluidity even near body temperature, not only under the abdominal wall incision and injured area where adhesions are clearly predicted, but also intestinal tract (especially small intestine) where adhesions are difficult to predict. It has the advantage of being able to contact or adhere the active ingredient to the entire surface of the tissue over a wide area within the abdominal cavity.
  • the adhesion-preventing agent of the present invention is not limited to the abdominal wall incision or the injured part in this way, and can prevent a wide range of adhesions in the abdominal cavity. Adhesions involving the intestinal tract (particularly the small intestine) that cause intestinal obstruction can be prevented.
  • the anti-adhesion agent of the present invention can effectively prevent adhesions during the period required for healing of the injured site, and thus can reduce complications due to adhesions. Since it is absorbed into the body after healing, it does not cause new adhesion due to foreign body reaction or the like.
  • the anti-adhesion agent of the present invention is typically a dosage form of a dispersion liquid containing an active ingredient, it does not need to undergo complicated treatment (pre-preparation, shape adjustment, etc.) before use, and is excellent in handleability. There is.
  • the dispersion since the dispersion has an appropriate fluidity from room temperature to around body temperature, it can be applied to a wide range of the abdominal cavity including the surface of the injured site (dropping, spraying, coating, dipping), injection, etc. )can do. Therefore, the anti-adhesion agent is suitably used not only in open surgery but also in minimally invasive endoscopic surgery.
  • the anti-adhesion agent of the present invention contains anionized nanomaterials as an active ingredient, it is considered that the above-mentioned excellent anti-adhesion effect is exhibited.
  • unmodified nanomaterials or cationized nanomaterials cannot exert the adhesion-preventing effect as in the present invention, but rather may exacerbate adhesions (FIGS. 2-4 and). 9. See Comparative Examples 1 and 4-7).
  • carboxymethyl cellulose (CMC) having a cellulose molecular chain (diameter of about 0.4 nm) having an average diameter of sub-nano order has an excellent anti-adhesion effect as in the present invention in the dosage form of the solution even if it is anionized. Not obtained (see FIGS. 2 and 3, Comparative Examples 2 and 3).
  • the anti-adhesion agent of the present invention is characterized by containing at least one anionic nanomaterial selected from the group consisting of anionized nanocellulose and anionized nanochitin as an active ingredient.
  • the anti-adhesion agent of the present invention preferably contains an anionized nanomaterial and a liquid medium, and is preferably a dispersion liquid in which the anionized nanomaterial is dispersed in the liquid medium.
  • nanocellulose is a material containing plant fibers (for example, wood pulp) obtained by unraveling the fibers to the nano-size level.
  • the fiber diameter referred to here means the diameter of the fiber.
  • the anionized nanocellulose of the present invention is one in which a part of the hydroxyl group of glucose on the cellulose molecular chain existing on the surface of the nanocellulose is anionized, that is, chemically modified to an anionic group. Therefore, it may be referred to as anion-modified nanocellulose.
  • nanocellulose may have different basic structures due to the manufacturing method thereof, and based on the difference, for example, fibrous cellulose nanofibers (hereinafter, also referred to as "CNF”) and crystal-like ones. Can be classified into cellulose nanocrystals (hereinafter also referred to as "CNC").
  • CNF fibrous cellulose nanofibers
  • CNC crystal-like ones
  • the average fiber diameter of the anionized CNF of the present invention is usually 3 to 100 nm, preferably 3 to 50 nm, and more preferably 3 to 10 nm.
  • the average fiber length is usually 0.3 to 200 ⁇ m, preferably 0.5 to 50 ⁇ m, and more preferably 0.5 to 10 ⁇ m.
  • the aspect ratio is usually 50 or more, preferably 50 to 10000, and more preferably 50 to 1000.
  • the average means an arithmetic mean.
  • the average fiber diameter of the anionized CNC of the present invention is usually 3 to 100 nm, preferably 3 to 50 nm, and more preferably 3 to 10 nm.
  • the average fiber length is usually 100 to 400 nm, preferably 100 to 300 nm, and more preferably 100 to 200 nm.
  • the aspect ratio is usually less than 50.
  • the anionized nanocellulose of the present invention is an anionized version of each of the CNF and CNC, and has the characteristics of each of the above CNF and CNC.
  • the anionized nanocellulose of the present invention includes anionized cellulose nanofibers (hereinafter, also referred to as “anionized CNF”) and anionized cellulose nanocrystals (hereinafter, also referred to as “anionized CNC”). It is a concept that includes both.
  • the anionic group of the anionized nanocellulose of the present invention is a group that can be deprotonated and carry a negative charge, for example, a carboxyl group (-COOH) and a sulfate ester group (-O-SO). 3 H), phosphate ester group (-O-PO 3 H 2 ), carboxymethyl group (-CH 2 COOH), subphosphate ester group (-P (OR) 3 , -P (O) (OR) 2
  • R is independently a hydrogen atom or an organic group (for example, an alkyl group or the like), a nitrate ester group (-O-NO 2 H) or the like.
  • nanocellulose having a carboxyl group hereinafter, also referred to as “carboxylated nanocellulose”
  • nanocellulose having a sulfate ester group hereinafter, “sulfate esterified nanocellulose”.
  • nanocellulose having a phosphate ester group hereinafter also referred to as “phosphate esterified nanocellulose”
  • nanocellulose having a carboxymethyl group hereinafter also referred to as “carboxymethylated nanocellulose”
  • salts with cationic atoms or atomic groups may form salts with cationic atoms or atomic groups, if necessary.
  • the salt include salts of alkali metals (for example, lithium, sodium, potassium and the like), ammonium salts, salts with organic ammonium (for example, tetraalkylammonium and the like) and the like. It is preferably a salt of an alkali metal, more preferably a sodium salt.
  • the anionized nanocellulose of the present invention is used to include the above-mentioned nanocellulose having an anionic group and a salt thereof.
  • Carboxylated nanocellulose has a structure in which the 6-position hydroxyl group of glucose or the 2- and 3-position hydroxyl groups of glucose chemically modified to a carboxyl group. For example, a part of the hydroxyl group at the 6-position is oxidized and converted into a carboxyl group (for example, an oxidation method using TEMPO), and a part of the hydroxyl groups at the 2-position and the 3-position is oxidized and converted into a carboxyl group. (For example, an oxidation method using sodium hypochlorite pentahydrate) and the like. Carboxylated nanocellulose is according to or according to known methods such as JP-A-2008-001728, JP-A-2017-155024, International Publication No. 2018/230354, ACS Sustainable Chem Eng 2020, 8, 17800-17806 and the like. Can be manufactured.
  • the concentration of carboxyl groups (the amount of functional group introduced) in the carboxylated nanocellulose is usually 0.1 to 10 mmol / g, preferably 0.1 to 5 mmol / g, and more preferably 0.1 to 2 It is .5 mmol / g.
  • the amount of functional group introduced can usually be determined by neutralizing and titrating an aqueous dispersion (slurry) containing carboxylated nanocellulose with an alkaline aqueous solution (for example, an aqueous sodium hydroxide solution). For example, it can be measured according to the description of [Measurement of introduced functional group content 1] in Examples.
  • Sulfate-esterified nanocellulose usually has a structure in which some of the hydroxyl groups at the 2-position, 3-position and / or 6-position of glucose constituting the cellulose present on the surface of the nanocellulose are chemically modified with sulfuric acid. .. Sulfate-esterified nanocellulose can be produced according to or according to known methods such as International Publication No. 2018/131721.
  • the concentration of the sulfate ester group (the amount of the functional group introduced) in the sulfate-esterified nanocellulose is usually 0.1 to 10 mmol / g, preferably 0.1 to 5 mmol / g, and more preferably 0.1. It is ⁇ 2.5 mmol / g.
  • the amount of functional group introduced can usually be determined by neutralizing and titrating an aqueous dispersion (slurry) containing sulfate-esterified nanocellulose with an alkaline aqueous solution (for example, an aqueous sodium hydroxide solution). For example, it can be measured according to or according to the description of [Measurement of introduced functional group content 2] in Examples.
  • Phosphoric acid esterified nanocellulose usually has a structure in which some of the hydroxyl groups at the 2-position, 3-position and / or 6-position of glucose constituting the cellulose present on the surface of the nanocellulose are chemically modified with phosphoric acid. ing. Phosphoric acid esterified nanocellulose can be produced according to or according to known methods such as International Publication No. 2014/185505.
  • the concentration of the phosphate ester group (the amount of the functional group introduced) in the phosphate esterified nanocellulose is usually 0.1 to 10 mmol / g, preferably 0.1 to 5 mmol / g, and more preferably 0. .1 to 2.5 mmol / g.
  • the amount of the functional group introduced can be measured, for example, according to or according to the description of [Measurement of introduced functional group content 2] in Examples.
  • the concentration of the carboxymethyl group (the amount of the functional group introduced) in the carboxymethylated nanocellulose is usually 0.06 to 3.82 mmol / g, preferably 0.3 to 3.64 mmol / g, and more preferably. Is 0.6 to 3.44 mmol / g.
  • the amount of the functional group introduced can be measured, for example, according to or according to the description of [Measurement of introduced functional group content 1] in Examples.
  • the anti-adhesion agent of the present invention may contain one or more kinds of anionized nanocellulose.
  • anionized nanocelluloses anionized CNCs are preferable to anionized CNFs from the viewpoint of further improving the effect of preventing adhesions.
  • Chitin is the main component of the cuticle that covers the body surface of many invertebrates such as the exoskeleton of arthropods and crustaceans, that is, the outer skin, and the surface of the shell of soft animals, and the cell wall of fungi such as mushrooms.
  • Chitin is a linear nitrogen-containing polysaccharide polymer, which means poly- ⁇ 1-4-N-acetylglucosamine, which has a structure similar to that of cellulose, but the hydroxyl group of the 2-carbon is an acetamide group. It has become. That is, it is a 1,4-polymer of N-acetylglucosamine.
  • Nanochitin is obtained by unraveling chitin obtained from the above raw materials to the nano-size level.
  • anionized nanochitin of the present invention a part of the hydroxyl group of N-acetylglucosamine existing on the surface of the nanochitin is anionized, that is, chemically modified to an anionic group. Therefore, it may be referred to as anion-denatured nanochitin.
  • nanochitin may have different basic structures due to its manufacturing method, and based on the difference, for example, fibrous chitin nanofibers (hereinafter, also referred to as “chitin NF”) and crystal-like It can be classified into chitin nanocrystals (hereinafter also referred to as “chitin NC”).
  • chitin NF fibrous chitin nanofibers
  • chitin NC crystal-like It can be classified into chitin nanocrystals
  • the average fiber diameter of the anionized chitin NF of the present invention is usually 3 to 100 nm, preferably 3 to 50 nm, and more preferably 3 to 10 nm.
  • the average fiber length is usually 0.5 to 200 ⁇ m, preferably 0.5 to 50 ⁇ m, and particularly preferably 0.5 to 10 ⁇ m.
  • the aspect ratio is usually 50 or more, preferably 50 to 10000, and more preferably 50 to 1000.
  • the average fiber diameter of the anionized chitin NC of the present invention is usually 3 to 100 nm, preferably 3 to 50 nm, and more preferably 3 to 10 nm.
  • the average fiber length is usually 100 to 400 nm, preferably 100 to 300 nm, and more preferably 100 to 200 nm.
  • the aspect ratio is usually less than 50.
  • the anionized nanochitin of the present invention is an anionized version of each of the chitin NF and chitin NC, and has the characteristics of each of the above chitin NF and chitin NC.
  • the anionized nanochitins of the present invention are anionized chitin nanofibers (hereinafter also referred to as "anionic chitin NF”) and anionized chitin nanocrystals (hereinafter also referred to as "anionized chitin NC"). It is a concept that includes both.
  • the anionic group of the anionized nanochitin of the present invention is a group that can be deprotonated and carry a negative charge, for example, a carboxyl group (-COOH) and a sulfate ester group (-O-SO 3). H), phosphate ester group (-O-PO 3 H 2 ), carboxymethyl group (-CH 2 COOH), subphosphate ester group (-P (OR) 3 , -P (O) (OR) 2 , Here, R is the same as described above), a nitrate ester group (—O—NO 2 H), and the like. Of these, the carboxyl group is preferable.
  • the anionized nanokittin of the present invention is preferably a nanokittin having a carboxyl group (hereinafter, also referred to as “carboxylated nanokittin”) and a nanokittin having a sulfate ester group (hereinafter, also referred to as “sulfate esterified nanokittin”). ), Nanokitin having a phosphate ester group (hereinafter, also referred to as “phosphate esterified nanokittin”), nanokitin having a carboxymethyl group (hereinafter, also referred to as “carboxymethylated nanokittin”) and the like.
  • salts with cationic atoms or atomic groups examples include salts of alkali metals (for example, lithium, sodium, potassium and the like), ammonium salts, salts with organic ammonium (for example, tetraalkylammonium and the like) and the like. It is preferably a salt of an alkali metal, more preferably a sodium salt.
  • the anionized nanochitin of the present invention is used to include the above-mentioned nanochitin having an anionic group and a salt thereof.
  • Carboxylated nanochitin usually has a structure in which a part of the hydroxyl group at the 6-position of N-acetylglucosamine present on the surface of nanochitin is chemically modified to a carboxyl group. For example, a part of the hydroxyl group at the 6-position is oxidized (for example, TEMPO oxidation) and converted into a carboxyl group.
  • Carboxylated nanochitin can be produced according to or according to known methods such as Biomacromolecules 2008, 9, 192-198 and the like.
  • the concentration of the carboxyl group (the amount of the functional group introduced) in the carboxylated nanochitin is usually 0.1 to 10 mmol / g, preferably 0.1 to 5 mmol / g, and more preferably 0.1 to 2. It is 5 mmol / g.
  • the amount of introduced functional group can be measured, for example, according to the description of [Measurement of introduced functional group content 1] in Examples.
  • Sulfuric acid esterified nanochitin usually has a structure in which a part of the hydroxyl groups at the 3-position and / or the 6-position of N-acetylglucosamine present on the surface of nanochitin is chemically modified with sulfuric acid.
  • Sulfate-esterified nanochitin can be produced according to or according to known methods such as Carbonates Polymers, 2018, 197, 349-358 and the like.
  • the concentration of the sulfate ester group (the amount of the functional group introduced) in the sulfated nanochitin is usually 0.1 to 10 mmol / g, preferably 0.1 to 5 mmol / g, and more preferably 0.1 to 0.1. It is 2.5 mmol / g.
  • the amount of the functional group introduced can be measured, for example, according to the description of [Measurement of introduced functional group content 2] in Examples.
  • the concentration of the phosphate ester group (the amount of the functional group introduced) in the phosphorylated nanochitin is usually 0.1 to 10 mmol / g, preferably 0.1 to 5 mmol / g, and more preferably 0. It is 1 to 2.5 mmol / g.
  • the amount of the functional group introduced can be measured, for example, according to the description of [Measurement of introduced functional group content 2] in Examples.
  • the concentration of the carboxymethyl group (the amount of the functional group introduced) in the carboxymethylated nanochitin is usually 0.06 to 3.82 mmol / g, preferably 0.3 to 3.64 mmol / g, and more preferably. It is 0.6 to 3.44 mmol / g.
  • the amount of the functional group introduced can be measured, for example, according to or according to the description of [Measurement of introduced functional group content 1] in Examples.
  • the anti-adhesion agent of the present invention may contain one or more anionized nanochitins.
  • anionized nanochitins of the present invention anionic chitin NC is preferable, and carboxylated chitin nanocrystals (hereinafter, also referred to as “carboxylated chitin NC”) are more preferable.
  • liquid medium that can be contained in the anti-adhesion agent of the present invention preferably contains pharmaceutically acceptable water. That is, the liquid medium is preferably an aqueous liquid medium.
  • aqueous liquid medium examples include sterile water, purified water, distilled water, ion-exchanged water, ultrapure water and the like; physiological saline solution, sodium chloride aqueous solution, potassium chloride aqueous solution, calcium chloride aqueous solution, magnesium chloride aqueous solution, and the like.
  • Electrolyte aqueous solution such as sodium sulfate aqueous solution, potassium sulfate aqueous solution, sodium carbonate aqueous solution, sodium hydrogen carbonate aqueous solution, sodium acetate aqueous solution, Ringer's solution; buffer solution such as phosphate buffer solution, Tris hydrochloric acid buffer solution; glycerin, ethylene glycol, ethanol, isopropyl alcohol
  • Aqueous solution containing water-soluble organic substances such as; aqueous solution containing sugar molecules such as glucose, sucrose, maltose; aqueous solution containing water-soluble polymers such as polyethylene glycol and polyvinyl alcohol; octylglucoside, dodecylmaltoside, pluronic (registered trademark).
  • Aqueous solution containing a surfactant such as (polyethylene glycol / polypropylene glycol / polyethylene glycol copolymer); intracellular fluid, extracellular fluid, interstitial fluid, lymph fluid, spinal fluid, blood, gastric fluid, serum, plasma, saliva, Body fluids such as tears, semen, and urine; or a mixed solution thereof and the like can be mentioned.
  • a surfactant such as (polyethylene glycol / polypropylene glycol / polyethylene glycol copolymer); intracellular fluid, extracellular fluid, interstitial fluid, lymph fluid, spinal fluid, blood, gastric fluid, serum, plasma, saliva, Body fluids such as tears, semen, and urine; or a mixed solution thereof and the like can be mentioned.
  • purified water, physiological saline solution, Ringer's solution and the like are preferable.
  • the anti-adhesion agent of the present invention is further antibacterial, if necessary, from the viewpoints of improving storage stability, promoting therapeutic effect and anti-adhesion effect, improving handleability, preventing bacterial infection, and the like.
  • Pharmacological components such as agents, antibiotics, anti-inflammatory agents, blood circulation improving agents, steroids, enzyme inhibitors, growth factors, various vitamins; excipients, viscosity regulators, gelling agents, pH regulators, buffers, preservatives Additives such as agents, antioxidants and colorants; gas carriers such as nitrogen gas and carbon dioxide gas may be contained.
  • a dispersion liquid (particularly, an aqueous liquid medium) in which anionized nanomaterials are dispersed in a liquid medium (particularly, an aqueous liquid medium) is dispersed (particularly). It is preferably a dosage form of an aqueous dispersion).
  • the anti-adhesion agent of the present invention may contain one or more anionized nanomaterials. When the anti-adhesion agent of the present invention is a dispersion, the dispersion contains an effective amount of anionized nanomaterials that exert an anti-adhesion effect.
  • the concentration of the anionized nanomaterial contained in the anti-adhesion agent (dispersion liquid) is usually 0.01 to 10% by weight (wt%) with respect to the total amount of the anti-adhesion agent (dispersion liquid). It is preferably 0.1 to 5% by weight, more preferably 0.2 to 3% by weight, and particularly preferably 0.3 to 2% by weight.
  • the anti-adhesion agent of the present invention contains anionic nanomaterials as an active ingredient for preventing adhesions, and is preferably essential from anionic nanomaterials as an active ingredient, and more preferably anionized as an active ingredient. It consists only of nanomaterials.
  • the content of the anionized nanomaterial in the total solid content of the anti-adhesion agent is usually 25% by weight or more, preferably 30 to 100% by weight, and more preferably 30 to 80% by weight. It is particularly preferably 30 to 60% by weight.
  • the anti-adhesion agent of the present invention contains additives such as electrolytes and sugars.
  • the anti-adhesion agent of the present invention is a dispersion
  • the viscosity of the anti-adhesion agent (dispersion liquid) is usually 0.5 to 2000 mPa ⁇ s when the temperature is 0 to 40 ° C. (further, 25 to 37 ° C., particularly around 37 ° C.), and 0. It is preferably 5 to 1000 mPa ⁇ s.
  • anionized nanocrystals it is more preferably 0.5 to 100 mPa ⁇ s.
  • the anti-adhesion agent (dispersion solution) can be brought into contact with or adhered not only to the injured site where adhesion is predicted to occur, but also to the entire tissue surface in the abdominal cavity including the site where adhesion is difficult to be predicted.
  • the viscosity can be measured using a rotary viscometer as described in Examples.
  • the pH of the anti-adhesion agent of the present invention is usually 4 to 8, preferably 6 to 7.5, from the viewpoint of safety to the living body.
  • the anti-adhesion agent of the present invention may be a dosage form of the above dispersion, for example, a liquid agent; a spray agent such as an aerosol agent or a pump spray agent; a coating agent; an injection agent or the like. Depending on its usage pattern, it can be applied directly on the tissue and can be formulated into a dosage form having good operability.
  • the anti-adhesion agent according to the present invention may be a composition further containing a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier can be selected according to the dosage form to be used, and may be a gas carrier, a liquid carrier, or the like.
  • a preferred embodiment of the anti-adhesion agent is an aqueous dispersion containing an anionic nanomaterial and a liquid medium (particularly an aqueous liquid medium), wherein the anionic nanomaterial has a carboxyl group.
  • the concentration of the carboxylated nanocellulose is 0.1 to 2.5 mmol / g, and the concentration of the carboxylated nanocellulose contained in the anti-adhesion agent is 0.3 to 2.
  • weight% (wt%) the content of anionized nanomaterials in the total solids contained in the anti-adhesion agent is 30 to 100% by weight, and the temperature is 25 to 37 ° C. (particularly around 37 ° C.).
  • anti-adhesion agents having a viscosity of 0.5 to 2000 mPa ⁇ s (particularly 0.5 to 1000 mPa ⁇ s).
  • a preferred embodiment of the anti-adhesion agent is an aqueous dispersion comprising an anionized nanomaterial and a liquid medium (particularly an aqueous liquid medium), wherein the anionic nanomaterial has a sulfate ester group concentration.
  • It is a sulfate-esterified nanocellulose (particularly, sulfate-esterified CNC) having a concentration of 0.1 to 2.5 mmol / g, and the concentration of the sulfate-esterified nanocellulose contained in the anti-adhesion agent is 0.3 to 2.
  • wt% the content of the anionized nanomaterial in the total solid content contained in the anti-adhesion agent is 30 to 100% by weight, and the temperature is 25 to 37 ° C. (particularly around 37 ° C.).
  • Examples of the anti-adhesion agent have a viscosity of 0.5 to 2000 mPa ⁇ s (particularly 0.5 to 1000 mPa ⁇ s).
  • a preferred embodiment of the anti-adhesion agent is an aqueous dispersion comprising an anionic nanomaterial and a liquid medium (particularly an aqueous liquid medium), wherein the anionic nanomaterial has a concentration of phosphate ester groups.
  • the concentration of the phosphate-esterified nanocellulose is 0.1 to 2.5 mmol / g
  • the concentration of the phosphate-esterified nanocellulose contained in the anti-adhesion agent is 0. .3 to 2% by weight (wt%)
  • the content of anionized nanomaterials in the total solids contained in the anti-adhesion agent is 30 to 100% by weight
  • the temperature is 25 to 37 ° C. (particularly).
  • anti-adhesion agents having a viscosity at 0.5 to 2000 mPa ⁇ s (particularly 0.5 to 1000 mPa ⁇ s) at (around 37 ° C.).
  • a preferred embodiment of the anti-adhesion agent is an aqueous dispersion comprising an anionic nanomaterial and a liquid medium (particularly an aqueous liquid medium), wherein the anionic nanomaterial has a concentration of carboxymethyl groups.
  • It is a carboxymethylated nanocellulose (particularly, carboxymethylated CNC) having a concentration of 0.06 to 3.82 mmol / g, and the concentration of the carboxymethylated nanocellulose contained in the anti-adhesion agent is 0.3 to 2 By weight% (wt%), the content of anionized nanomaterials in the total solids contained in the anti-adhesion agent is 30 to 100% by weight, and the temperature is 25 to 37 ° C. (particularly around 37 ° C.).
  • anti-adhesion agents having a viscosity of 0.5 to 2000 mPa ⁇ s (particularly 0.5 to 1000 mPa ⁇ s).
  • a preferred embodiment of the anti-adhesion agent is an aqueous dispersion containing an anionized nanomaterial and a liquid medium (particularly an aqueous liquid medium), wherein the anionic nanomaterial has a carboxyl group concentration of 0. .
  • Carboxylated nanochitin (particularly, carboxylated chitin NC) having a concentration of 1 to 2.5 mmol / g, and the concentration of carboxylated nanochitin contained in the anti-adhesion agent is 0.3 to 2% by weight (wt%).
  • the content of the anionized nanomaterial in the total solid content contained in the anti-adhesion agent is 30 to 100% by weight, and the viscosity at a temperature of 25 to 37 ° C. (particularly around 37 ° C.) is 0. Examples thereof include adhesion-preventing agents having a value of 5 to 2000 mPa ⁇ s (particularly 0.5 to 1000 mPa ⁇ s).
  • the anti-adhesion agent according to the present invention preferably contains anionized nanomaterials and a liquid medium, and further contains other components as necessary to the extent that the anti-adhesion effect of the present invention can be exhibited. It may be added.
  • Anti-adhesion agents can usually be prepared by mixing anionized nanomaterials with a liquid medium. Specifically, it can be prepared by uniformly dispersing anionized nanomaterials in a liquid medium. As a dispersion method, it can be prepared by uniformly dispersing using an ultrasonic dispersion method, a stirring method (for example, a homomixer or the like) or the like.
  • the anti-adhesion agent of the present invention is applied to organs, tissues, etc. in the abdominal cavity, it is preferably sterilized.
  • sterilization process known methods such as high-pressure steam sterilization, filtration sterilization, and electron beam sterilization can be adopted.
  • the anti-adhesion agent of the present invention can effectively prevent adhesions by using (applying) it to a site that prevents adhesions.
  • Examples of the site for preventing adhesion include an inflamed site or a damaged site in a human or animal organ, tissue, or the like.
  • an incision site in surgery an injured site artificially caused by treatment during surgery, an endogenous or extrinsic inflammation site in the body, and the like can be mentioned.
  • organs include stomach, small intestine, large intestine, duodenum, mesentery, peritoneum, cecum, liver, heart, heart membrane, lung, brain, ovary, uterus, spleen, omentum, eyeball, and the like.
  • Examples include bone, spine, nerve, cartilage, ligament, tendon, skin, duct (blood vessel, oviduct, etc.), fat and the like.
  • the anti-adhesion agent of the present invention is a liquid dispersion having a low viscosity and an appropriate fluidity (for example, an aqueous dispersion), whereby adhesion is clearly predicted to occur under the abdominal wall incision or damage. Adhesions can be prevented by contacting or adhering the active ingredient not only to the site but also to the entire surface of a wide range of tissues in the abdominal cavity such as the intestinal tract where the adhesion occurrence site is difficult to predict, especially the small intestine.
  • the anti-adhesion agent of the present invention can be used as a dosage form of a liquid dispersion (for example, an aqueous dispersion), and is usually used as a liquid agent, a spray agent (aerosol agent, a pump spray agent, etc.), a coating agent, an injection agent, or the like. It can be formulated.
  • This pharmaceutical product can be administered by dropping, exposing, spraying, applying or the like to the surface of a site where adhesion is prevented.
  • the amount of the anti-adhesion agent used is not particularly limited as long as it can exert its anti-adhesion effect.
  • the anti-adhesion agent liquid dispersion
  • the anti-adhesion agent of the present invention remains as it is without undergoing complicated pretreatment such as pre-use formulation required for a two-component anti-adhesion agent and adjustment of the shape or size required for a sheet-shaped anti-adhesion material. It is easy to handle because it can be applied to the part that prevents adhesions. Therefore, it is particularly preferably used in minimally invasive endoscopic surgery.
  • the solid content concentration was measured using a moisture meter (MOC63u, manufactured by Shimadzu Corporation).
  • the solid content concentration of the dispersion was measured in the standard automatic drying stop mode (drying temperature: 105 ° C., end condition: moisture change rate for 30 seconds was 0.05% or less).
  • the fiber shape was measured using a scanning probe microscope. 10 ⁇ L of the dispersion diluted to 0.005% by weight (wt%) with ultrapure water was added dropwise to the mica substrate and dried at room temperature to prepare a sample for observation. The sample is set in a scanning probe microscope (environmental control unit E-sweep, manufactured by Hitachi High-Tech Science Co., Ltd.), and a fiber image is acquired in DFM mode using the micro cantilever SI-DF40 (manufactured by Hitachi High-Tech Science Co., Ltd.). (FIG. 1 (a), FIG. 1 (b) and FIG. 1 (c)).
  • carboxyl group concentration was determined according to the following formula.
  • Carboxyl group concentration (mmol / g) V (mL) x 0.05 / Nanocellulose weight (g)
  • Carboxyl group concentration (mmol / g) V (mL) x 0.05 / nanochitin weight (g)
  • the concentration of the phosphate ester group or the sulfate ester group was determined according to the following formula.
  • Phosphoric acid ester group concentration (mmol / g) V (mL) x 0.1 / nanocellulose weight (g)
  • Sulfate ester group concentration (mmol / g) V (mL) x 0.1 / nanocellulose weight (g)
  • the viscosity is measured using a rotary viscometer (HAAKE RS-6000, manufactured by Thermo Fisher Scientific Co., Ltd.). Actually, in Rot mode (rotational viscosity measurement), each dispersion is placed on a lower plate (Lower Plate TMP60) and measured using a sensor (Cone C60 / 1 ° Ti L) (Rot time dependence measurement; Mode: CR, shear rate: 100 1 / s, gap 0.052 mm, temperature: 25 ° C. and 37 ° C.), and the average viscosity value up to 5 minutes after the start of measurement was measured. The viscosity of pure water was 0.83 mPa ⁇ s at 25 ° C. and 0.70 mPa ⁇ s at 37 ° C.
  • a carboxyl group-introduced CNF was produced with reference to the prior art (Japanese Patent Laid-Open No. 2013-249448, Production of Cellulose Fiber B6). Specifically, 150 mL of water, 0.25 g of sodium bromide, and 0.025 g of TEMPO reagent are added to 2 g of softwood pulp so that a 13 wt% sodium hypochlorite aqueous solution (cooxidant) becomes 24.0 mmol / g. In addition, the reaction was started.
  • reaction time was 120 minutes.
  • 0.1N hydrochloric acid was added for neutralization, filtration and washing with water were repeated for purification, and then the surface of microfibrils was oxidized to obtain cellulose fibers.
  • pure water was added to adjust the solid content concentration to 4 wt%.
  • the pH of the slurry was adjusted to 10 with a 24% aqueous sodium hydroxide solution, 0.2 mmol / g of sodium borohydride was added to the cellulose fibers at a temperature of 30 ° C., and the mixture was reacted for 2 hours for reduction treatment. did.
  • 0.1N hydrochloric acid was added to neutralize the mixture, and the mixture was purified by repeating filtration and washing with water to obtain cellulose fibers. Pure water was added thereto, diluted to 1 wt%, and treated once with a high-pressure homogenizer (manufactured by Sanwa Engineering Co., Ltd., H11) at a pressure of 100 MPa to produce a CNF having a carboxyl group introduced therein.
  • Example 1 (Preparation of carboxylated CNF dispersion)
  • the solid content concentration of the above-mentioned carboxyl group-introduced CNF was 0.2 wt% (Example 1), 0.4 wt% (Example 2), 0.8 wt% (Example 3) and 1.2 wt% (implementation).
  • Uniform carboxylation CNF by adding distilled water (Otsuka distilled water, manufactured by Otsuka Pharmaceutical Factory Co., Ltd.) and then treating with a high-speed rotary mixer (Polytron homogenizer, manufactured by Central Kagaku Trading Co., Ltd.) so as to be in Example 4).
  • a dispersion was obtained.
  • the obtained dispersion was subjected to high-pressure steam sterilization treatment at 121 ° C. for 20 minutes.
  • a sheet of softwood bleached kraft pulp was treated with a cutter mill and a pin mill to form cotton-like fibers, and then 30 g of the fibers were taken by absolute dry weight and uniformly sprayed with a phosphorylation reagent to obtain chemical-impregnated pulp.
  • the chemical-impregnated pulp was heat-treated for 120 minutes in a blower dryer equipped with a damper heated to 140 ° C. to obtain phosphoric acid esterified pulp. 3 g of this was taken by mass of pulp, 300 mL of ion-exchanged water was added, the mixture was stirred and uniformly dispersed, and then the process of filtering and dehydrating to obtain a dehydrated sheet was repeated twice.
  • the obtained dehydration sheet was diluted with 300 mL of ion-exchanged water, 1N sodium hydroxide was added dropwise with stirring, and 300 mL of ion-exchanged water was added to obtain a pulp slurry having a pH of 12 to 13. After dehydrating this pulp slurry to obtain a dehydrated sheet, 300 mL of ion-exchanged water was added, and the mixture was stirred and uniformly dispersed, and then filtered and dehydrated to obtain a dehydrated sheet. The process was repeated twice. Ion-exchanged water was added to the dehydrated sheet of the phosphoric acid esterified pulp obtained after washing and dehydration, and the mixture was stirred to make a 0.5 wt% slurry. This slurry was treated at 21500 rpm for 30 minutes using a defibrating treatment device (Clearmix-2.2S, manufactured by M-Technique) to produce a CNF into which a phosphate ester group was introduced.
  • Example 5 (Preparation of phosphate esterified CNF dispersion) Distilled water was added to the CNF into which the above-mentioned phosphoric acid ester group was introduced so that the solid content concentration was 0.8 wt% (Example 5) and 1.2 wt% (Example 6), and then treated with a high-speed rotary mixer. A uniform phosphate esterified CNF dispersion was obtained. The obtained dispersion was subjected to high-pressure steam sterilization treatment at 121 ° C. for 20 minutes.
  • a CNF introduced with a sulfate ester group was produced with reference to the prior art (International Publication No. 2018/131721, Example 14). Specifically, 18 g of DMSO, 2 g of acetic anhydride (concentration in the defibration solution is 9.8 wt%) and 0.5 g of sulfuric acid (concentration in the defibration solution is 2.4 wt%) are placed in a 50 mL sample bottle and sufficiently stirred. After that, a defibration solution was prepared. 0.6 g of cellulose pulp was added to this defibration solution, and the mixture was stirred at room temperature (23 ° C.) for 80 minutes.
  • Example 7 (Preparation of sulfate esterified CNF dispersion) Distilled water was added to the CNF into which the above sulfate ester group was introduced so that the solid content concentration was 0.8 wt% (Example 7), and then a high-speed rotary mixer treatment was performed to uniformly disperse the sulfate esterified CNF. Obtained liquid.
  • Example 8 to 13 (Preparation of carboxylated CNC dispersion)
  • a CNC having a carboxyl group introduced at the 6-position of glucose on the surface of cellulose microfibrils a commercially available carboxylated CNC (manufactured by Cellulose Lab, TEMPO oxide, functional group concentration 1.2 or 2.0 mmol / g, solid content concentration 2) .0 wt%) was used.
  • Solid content concentration is 0.1 wt% (Example 8), 0.5 wt% (Example 9), 1.0 wt% (Example 10), 1.5 wt% (Example 11) and 2.0 wt% (implementation).
  • Example 12 distilled water was added so as to have a concentration of 1.2 wt% (Example 13), and then a high-speed rotary mixer treatment was performed to obtain a uniform carboxylated CNC dispersion. The obtained dispersion was subjected to high-pressure steam sterilization treatment at 121 ° C. for 20 minutes.
  • CNC having a carboxyl group introduced With reference to the prior art (International Publication No. 2018/230354, ACS Sustainable Chem Eng 2020, 8, 17800-17806), a CNC having a carboxyl group introduced at the 2- and 3-positions of glucose on the surface of cellulose microfibrils was produced. Specifically, water, 6M hydrochloric acid, and unmodified CNC (solid content 1 g) were added to 42.8 g of sodium hypochlorite pentahydrate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), and the mixture was stirred to a concentration of 22. %, pH 11.0 aqueous solution.
  • Example 14 (Preparation of carboxylated CNC dispersion) Distilled water (Otsuka distilled water, manufactured by Otsuka Pharmaceutical Factory Co., Ltd.) was added to the above-mentioned carboxyl group-introduced CNC so that the solid content concentration became 1.0 wt% (Example 14), and a carboxylated CNC dispersion was prepared. Obtained. The obtained dispersion was subjected to high-pressure steam sterilization treatment at 121 ° C. for 20 minutes.
  • Distilled water Otsuka distilled water, manufactured by Otsuka Pharmaceutical Factory Co., Ltd.
  • CNC with sulfate ester group introduced A CNC having a sulfate ester group introduced was produced with reference to the prior art (Cellulose Commun, 2016, 23, 193-199). Specifically, 10 g of wood-derived microcrystalline cellulose (Nacalai Tesque, Inc.) was suspended in 100 mL of 65% sulfuric acid, and the mixture was stirred at 45 ° C. for 60 minutes. 200 mL of distilled water was added to stop the reaction. The reaction mixture was centrifuged, the supernatant was discarded by decantation, an appropriate amount of distilled water was added to the precipitate, and the mixture was completely suspended by shaking vigorously, and then centrifuged again.
  • wood-derived microcrystalline cellulose Nacalai Tesque, Inc.
  • This washing step was repeated while the supernatant after centrifugation was clear. After centrifugation, when the supernatant became cloudy, the supernatant was collected. The recovery process was continued while the supernatant was turbid, and the recovery was completed when the turbidity disappeared.
  • the recovered CNC suspension was placed in a dialysis membrane (MWCO14000) and dialyzed until the external dialysis solution became neutral. The CNC suspension was immersed in a 10% concentration polyethylene glycol (molecular weight 20000) solution while still in the dialysis membrane, and concentrated until the solid content concentration became about 2%.
  • Example 15 (Preparation of sulfate esterified CNC dispersion) Distilled water (Otsuka Distilled Water, manufactured by Otsuka Pharmaceutical Factory Co., Ltd.) was added to the above-mentioned CNC into which the sulfate ester group was introduced so that the solid content concentration became 1.0 wt% (Example 15), and the sulfate esterified CNC was dispersed. Obtained liquid. The obtained dispersion was subjected to high-pressure steam sterilization treatment at 121 ° C. for 20 minutes.
  • Distilled water Otsuka Distilled Water, manufactured by Otsuka Pharmaceutical Factory Co., Ltd.
  • CNC with carboxymethyl group introduced
  • a carboxymethyl group-introduced CNC was produced with reference to the prior art (LWT-Food Science and Technology, 2017, 86, 318-326). Specifically, 1 g of CNC powder (manufactured by Cellulose Lab) was suspended in 100 mL of isopropanol and stirred. 1 mL of a 12N sodium hydroxide aqueous solution was added dropwise, and stirring was continued. 1.42 g of chloroacetic acid was dissolved in 15 mL of isopropanol, added dropwise as a solution, and the mixture was stirred at 50 ° C. for 50 minutes.
  • Example 16 (Preparation of carboxymethylated CNC dispersion) After dissolving the above-mentioned carboxymethyl group-introduced CNC in distilled water (Otsuka distilled water, manufactured by Otsuka Pharmaceutical Factory, Inc.) so that the solid content concentration becomes 1.0 wt% (Example 16), the temperature is 121 ° C. , 20 minutes of high pressure steam sterilization treatment.
  • distilled water Otsuka distilled water, manufactured by Otsuka Pharmaceutical Factory, Inc.
  • Carboxylated chitin NC was produced with reference to the method of Fan et al. (Biomacromolecules 2008, 9, 192-198). Specifically, 300 mL of water, 0.3 g of sodium bromide, and 0.048 g of TEMPO reagent were added to 3 g of chitin powder (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), and sodium hypochlorite pentahydrate (effective chlorine). (39% or more) 10.1 g was added, and the reaction was started at room temperature.
  • the pH of the dispersion was maintained at 10 while dropping a 0.5 N aqueous sodium hydroxide solution, and the reaction was carried out for 45 minutes, and then 10 mL of ethanol (99.5) was added to stop the oxidation reaction.
  • 10 mL of ethanol (99.5) was added to stop the oxidation reaction.
  • the supernatant was removed by centrifugation. Ultrapure water was added to the remaining precipitate, and the mixture was stirred until uniformly dispersed. The supernatant was removed by centrifugation, and the same operation was repeated 3 times.
  • Example 17 (Preparation of carboxylated chitin NC) Distilled water is added to the above-mentioned chitin NC into which the carboxyl group has been introduced so that the solid content concentration becomes 1.0 wt% (Example 17), and then a high-speed rotary mixer treatment is performed to uniformly disperse the carboxylated chitin NC. Obtained liquid.
  • Table 1 shows the measurement results of the properties (shape, functional group, viscosity of the dispersion) of the dispersions of Examples 1 to 17 and Comparative Examples 1 to 7.
  • Example 18 Adhesion-preventing effect of carboxylated CNF dispersion using mouse adhesion model-comparison with unmodified CNF dispersion and CMC solution) (Test method) Using 6 to 7 week old BALB / cA Jcl male mice (manufactured by Japan Claire Co., Ltd.), the cecum was exposed after laparotomy under mixed anesthesia of ketamine and xylazine.
  • adhesion prevention action can be obtained by the fact that the cellulose in the dispersion liquid is in the form of a fiber having a microfibril structure (aggregate of cellulose molecular chains) and the surface thereof is modified with a carboxyl group. It turned out.
  • Example 19 (Adhesion-preventing effect of carboxylated CNC dispersion using mouse adhesion model-comparison with unmodified CNC dispersion, quaternary ammonium-ammonized CNC dispersion, and CMC solution) (Test method) The test was conducted under the same method and conditions as in Example 18. Carboxylated CNC dispersion (Example 11), unmodified CNC dispersion (Comparative Example 4), quaternary ammonium-ammonized CNC dispersion (Comparative Example 5) or CMC solution (Comparative Example 3) was administered at 0.25 mL / body. did. The control group was the same amount of physiological saline. (Test results) The results of the adhesion evaluation are shown in FIG.
  • the carboxylated CNC dispersion clearly reduced the adhesion score compared to the control group.
  • the unmodified CNC dispersion, the quaternary ammonium-ammonized CNC dispersion and the CMC solution did not reduce the adhesion score. From these results, it was found that the cellulose in the dispersion liquid is in the form of a crystal having a microfibril structure, and the surface thereof is modified with a carboxyl group to obtain an adhesion-preventing effect.
  • the quaternary ammonium-modified CNC dispersion did not have an adhesion-preventing effect, it was inferred that it was important to make the modified functional group on the surface of the microfibrils anionic rather than cationic.
  • Example 20 (Adhesion-preventing effect of anionic CNF dispersion using rat small intestine adhesion model-comparison with unmodified CNF dispersion) (Test method) Using a 7-8 week old Crl: CD (SD) male rat (Japan Charles River Co., Ltd.), the abdomen was opened under mixed anesthesia of ketamine and xylazine, and the epididymal fat was resected. The ileocecal region was exposed to the outside of the body, and the small intestine within a range of 10 cm from the cecum was rubbed with dry gauze wrapped around the finger to the extent that bleeding was observed.
  • CD CD
  • the organ was returned to the abdominal cavity and the abdominal cavity was washed with 10 mL of physiological saline. The residual liquid after washing was removed by suction as much as possible. Then, a carboxylated CNF dispersion (Example 3), a phosphate esterified CNF dispersion (Example 5), a sulfate esterified CNF dispersion (Example 7), or an unmodified CNF dispersion (Comparative Example 1) was added. The abdomen was closed by intravenously instilling 2 mL / body into the abdomen. The control group was the same amount of physiological saline. For this test method, the method of Yamauchi et al. (Japanese Patent Laid-Open No.
  • the chemical modification of the microfibril surface of cellulose nanofibers is not limited to the carboxyl group, but the anti-adhesion effect can be obtained by substituting with an anionic functional group such as a phosphate ester group or a sulfate ester group. rice field.
  • Example 21 (Adhesion-preventing effect of various anionized CNC dispersions using a rat small intestine adhesion model-comparison with physiological saline) (Test method) The test was conducted under the same method and conditions as in Example 20. Carboxylated CNC dispersion (Example 14, the hydroxyl groups at the 2- and 3-positions of glucose are modified to carboxyl groups), sulfate-esterified CNC dispersion (Example 15), or carboxymethylated CNC dispersion (Example 16). was administered at 2 mL / body. In the control group, the same amount of physiological saline was used. (Test results) The results of the adhesion evaluation are shown in FIG.
  • the carboxylated CNC dispersion, the sulfate esterified CNC dispersion and the carboxymethylated CNC dispersion all reduced the length of adhesion as compared with the control group. From these results, it was found that the chemical modification of the microfibril surface of cellulose nanocrystals is not limited to the carboxyl group, but the anti-adhesion effect can be obtained by substituting with an anionic functional group such as a sulfate ester group or a carboxymethyl group. ..
  • Example 14 a CNC in which the hydroxyl groups at the 2- and 3-positions of glucose are modified to a carboxyl group (Example 14) and a CNC in which the hydroxyl group at the 6-position of glucose is modified to a carboxyl group as shown later in Example 23 (Example 10). Since all of them reduced the length of adhesion, it was found that there is no selectivity in the modification position of the carboxyl group in the adhesion preventing action.
  • Example 22 (Adhesion-preventing effect of carboxylated CNF dispersion using rat small intestine adhesion model-concentration dependence) (Test method) The test was conducted under the same method and conditions as in Example 20. 0.2 wt% (Example 1), 0.4 wt% (Example 2) and 0.8 wt% (Example 3) carboxylated CNF dispersions were administered at 2 mL / body. The control group was the same amount of physiological saline. (Test results) The results of the adhesion evaluation are shown in FIG. Adhesion length was reduced at concentrations of 0.2 wt%, 0.4 wt% and 0.8 wt% compared to the control group. Furthermore, the length of adhesion was significantly reduced at concentrations of 0.4 wt% and 0.8 wt%.
  • Example 23 (Adhesion-preventing effect of carboxylated CNC dispersion using rat small intestine adhesion model-concentration dependence) (Test method) The test was conducted under the same method and conditions as in Example 20. 0.1 wt% (Example 8), 0.5 wt% (Example 9), 1.0 wt% (Example 10), 1.5 wt% (Example 11) and 2.0 wt% (Example 12). The carboxylated CNC dispersion was administered at 2 mL / body. The control group was the same amount of physiological saline. (Test results) The results of the adhesion evaluation are shown in FIG. Adhesion length was reduced at all concentrations of 0.1-2.0 wt% compared to the control group. Furthermore, at 1.5 and 2.0 wt%, the length of adhesion was significantly reduced.
  • Example 24 Comparison of adhesion prevention effect between carboxylated CNF dispersion and carboxylated CNC dispersion using rat small intestine adhesion model
  • Test method The test was conducted under the same method and conditions as in Example 20. A 1.2 wt% carboxylated CNF dispersion (Example 4) and a 1.2 wt% carboxylated CNC (Example 13) dispersion were administered at 2 mL / body. The control group was the same amount of physiological saline. (Test results) The results of the adhesion evaluation are shown in FIG.
  • Example 25 (Adhesion-preventing effect of carboxylated chitin NC dispersion using rat small intestine adhesion model-comparison with unmodified chitin NF dispersion and chitosan NF dispersion) (Test method) The test was conducted under the same method and conditions as in Example 20. Carboxylated chitin NC dispersion (Example 17), unmodified chitin NF dispersion (Comparative Example 6), or chitosan NF dispersion (Comparative Example 7) was administered at 2 mL / body. The control group was the same amount of physiological saline. (Test results) The results of the adhesion evaluation are shown in FIG.
  • the carboxylated chitin NC dispersion clearly reduced the length of adhesions compared to the control group.
  • the unmodified chitin NF dispersion did not reduce the length of adhesions.
  • the cationic chitosan NF dispersion a clear exacerbation of adhesions was observed (6 out of 10 cases formed massive adhesions involving many organs, so the length of adhesions could not be measured accurately. Therefore, it was not possible to calculate the average length of adhesions). From these results, it was found that, as with cellulose, the surface of chitin's microfibrils is modified with a carboxyl group to obtain an anti-adhesion effect.
  • Example 26 (Adhesion-preventing effect of anionized CNF dispersion using a rabbit Achilles tendon adhesion model) (Test method) Using an 11-week-old Kbl: JW male rabbit (manufactured by Kitayama Labes Co., Ltd.), after shaving the skin around the Achilles tendon (soleus tendon) under mixed anesthesia with ketamine and xylazine, a special orthotic device and a cast (3M Japan Co., Ltd.) The knee joint was fixed at 90 ° and the ankle joint was fixed at 180 ° using (manufactured by the company).
  • the animals were fixed in the prone position, and the skin around the ankles was alternately wiped with povidone iodine (manufactured by Meiji Seika Pharma Co., Ltd.) and ethanol for disinfection (Fujifilm Wako Pure Chemical Industries, Ltd.) and thoroughly disinfected.
  • povidone iodine manufactured by Meiji Seika Pharma Co., Ltd.
  • ethanol for disinfection Feujifilm Wako Pure Chemical Industries, Ltd.
  • a 2.5 cm incision was made in the skin of the treated area, a 2 cm peripheral tissue was excised, and a soleus tendon was isolated.
  • the tendon was cut with a scalpel and then ligated with a 5-0 suture and sutured by the Modified-Kessler method. After confirming that there was no bleeding, the surgical site was washed with physiological saline.
  • a carboxylated CNF dispersion (Example 4) or a phosphate esterified CNF dispersion (Example 6) was intravenously administered to the surgical site at 0.30 mL / body to close the wound.
  • the control group was the same amount of physiological saline.
  • the skin was sutured with 3-0 nylon thread.
  • Medical absorbent cotton (Curelet, manufactured by Kawamoto Sangyo Co., Ltd.) was placed on the closed wound and covered with a cast bandage (Ortex, manufactured by Muranaka Medical Instrument Co., Ltd.). The cast was fixed from the thigh to the fingertips, and the cast was protected with an elastic bandage (Elastopore, manufactured by Nichiban Co., Ltd.).
  • the adhesion-preventing agent of the present invention can effectively prevent adhesions by applying it to a site that prevents adhesions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Composite Materials (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Sealing Material Composition (AREA)
  • Paints Or Removers (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
PCT/JP2021/020791 2020-06-01 2021-06-01 癒着防止剤及びそれを用いた癒着防止方法 Ceased WO2021246388A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020227046355A KR20230018490A (ko) 2020-06-01 2021-06-01 유착 방지제 및 그것을 이용한 유착 방지 방법
BR112022022193A BR112022022193A2 (pt) 2020-06-01 2021-06-01 Agente de prevenção de aderência e método para prevenção de aderência usando o mesmo
EP21817270.8A EP4159251A4 (en) 2020-06-01 2021-06-01 Adhesion-preventing agent and method for preventing adhesion using same
CN202180039187.4A CN115884800A (zh) 2020-06-01 2021-06-01 防粘连剂及使用其的粘连防止方法
MX2022015193A MX2022015193A (es) 2020-06-01 2021-06-01 Agente preventivo de adhesion y metodo preventivo de adhesion usando el mismo.
JP2022528834A JP7321610B2 (ja) 2020-06-01 2021-06-01 癒着防止剤及びそれを用いた癒着防止方法
US18/007,603 US20230226098A1 (en) 2020-06-01 2021-06-01 Adhesion-preventing agent and method for preventing adhesion using same
AU2021284433A AU2021284433A1 (en) 2020-06-01 2021-06-01 Adhesion-preventing agent and method for preventing adhesion using same
CA3189526A CA3189526A1 (en) 2020-06-01 2021-06-01 Adhesion-preventing agent and method for preventing adhesion using same
ZA2022/11627A ZA202211627B (en) 2020-06-01 2022-10-25 Adhesion-preventing agent and method for preventing adhesion using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020095280 2020-06-01
JP2020-095280 2020-06-01

Publications (1)

Publication Number Publication Date
WO2021246388A1 true WO2021246388A1 (ja) 2021-12-09

Family

ID=78831085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/020791 Ceased WO2021246388A1 (ja) 2020-06-01 2021-06-01 癒着防止剤及びそれを用いた癒着防止方法

Country Status (13)

Country Link
US (1) US20230226098A1 (https=)
EP (1) EP4159251A4 (https=)
JP (2) JP7321610B2 (https=)
KR (1) KR20230018490A (https=)
CN (1) CN115884800A (https=)
AR (1) AR122491A1 (https=)
AU (1) AU2021284433A1 (https=)
BR (1) BR112022022193A2 (https=)
CA (1) CA3189526A1 (https=)
MX (1) MX2022015193A (https=)
TW (1) TW202210113A (https=)
WO (1) WO2021246388A1 (https=)
ZA (1) ZA202211627B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114904053A (zh) * 2022-05-31 2022-08-16 重庆大学 一种基于纤维素纳米晶的抗炎防组织粘连生物涂层及其制备方法和应用
JP2022132201A (ja) * 2021-02-26 2022-09-07 国立大学法人信州大学 表面修飾多糖類ナノ材料、その分散液及び機能性物品

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102023116601A1 (de) 2022-06-29 2024-01-04 Semiconductor Energy Laboratory Co., Ltd. Licht emittierende Vorrichtung

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03167201A (ja) * 1989-10-31 1991-07-19 Pfizer Hospital Prod Group Inc 生体組織間の癒着の予防に有用な材料及びその調製法
JPH07101866A (ja) 1993-09-30 1995-04-18 Morishita Roussel Kk 腹腔内の癒着防止剤
WO2005000374A1 (ja) * 2003-06-30 2005-01-06 Denki Kagaku Kogyo Kabushiki Kaisha 脊椎・脊髄手術用癒着防止材
JP2008001728A (ja) 2006-06-20 2008-01-10 Asahi Kasei Corp 微細セルロース繊維
JP2013249448A (ja) 2012-06-04 2013-12-12 Dai Ichi Kogyo Seiyaku Co Ltd 無機微粒子含有組成物およびそれを用いた皮膜
WO2014185505A1 (ja) 2013-05-16 2014-11-20 王子ホールディングス株式会社 リン酸エステル化微細セルロース繊維及びその製造方法
WO2015099083A1 (ja) 2013-12-25 2015-07-02 日産化学工業株式会社 血清および血液を固化する水分散液
JP2017155024A (ja) 2016-03-04 2017-09-07 株式会社ユーグレナ 細胞増殖促進剤
WO2018131721A1 (ja) 2017-01-16 2018-07-19 株式会社Kri 硫酸エステル化修飾セルロースナノファイバーおよびセルロースナノファイバーの製造方法
WO2018230354A1 (ja) 2017-06-16 2018-12-20 東亞合成株式会社 セルロースナノファイバーの製造方法
US20190015564A1 (en) * 2017-07-14 2019-01-17 Soonchunhyang University Industry Academy Cooperation Foundation Adhesion prevention agent comprising injectable thermosensitive wood based-oxidized cellulose nanofiber

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610669B1 (en) * 1987-09-18 2003-08-26 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
JP5001246B2 (ja) 2008-09-26 2012-08-15 古河電池株式会社 蓄電池用モノブロック電槽
RU2012146357A (ru) * 2010-03-31 2014-05-10 Хоги Медикал Ко., Лтд. Предотвращающий адгезию материал
WO2013047218A1 (ja) * 2011-09-30 2013-04-04 日本製紙株式会社 セルロースナノファイバーの製造方法
JP6199858B2 (ja) * 2012-03-14 2017-09-20 日本製紙株式会社 アニオン変性セルロースナノファイバー分散液の製造方法
JP2015099083A (ja) 2013-11-19 2015-05-28 三菱重工業株式会社 酸露点腐食評価装置及び酸露点腐食評価方法
KR102232614B1 (ko) 2016-07-21 2021-03-29 난징 산홈 팔마세우티칼 컴퍼니 리미티드 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용
JP6958799B2 (ja) * 2017-05-25 2021-11-02 日本製紙株式会社 ハイドロゲル
SI3533458T1 (sl) * 2018-03-02 2023-09-29 Upm-Kymmene Corporation Medicinski izdelek, ki vsebuje bioaktivno molekulo, ki je imobilizirana na nanofibrilarno celulozo in postopek za njegovo pripravo
CN109966540B (zh) * 2019-04-04 2020-06-23 武汉大学 一种纳米甲壳素复合海藻酸钙医用敷料的制备方法及应用

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03167201A (ja) * 1989-10-31 1991-07-19 Pfizer Hospital Prod Group Inc 生体組織間の癒着の予防に有用な材料及びその調製法
JPH07101866A (ja) 1993-09-30 1995-04-18 Morishita Roussel Kk 腹腔内の癒着防止剤
WO2005000374A1 (ja) * 2003-06-30 2005-01-06 Denki Kagaku Kogyo Kabushiki Kaisha 脊椎・脊髄手術用癒着防止材
JP2008001728A (ja) 2006-06-20 2008-01-10 Asahi Kasei Corp 微細セルロース繊維
JP2013249448A (ja) 2012-06-04 2013-12-12 Dai Ichi Kogyo Seiyaku Co Ltd 無機微粒子含有組成物およびそれを用いた皮膜
WO2014185505A1 (ja) 2013-05-16 2014-11-20 王子ホールディングス株式会社 リン酸エステル化微細セルロース繊維及びその製造方法
JP2017025468A (ja) 2013-05-16 2017-02-02 王子ホールディングス株式会社 リン酸エステル化微細セルロース繊維及びその製造方法
WO2015099083A1 (ja) 2013-12-25 2015-07-02 日産化学工業株式会社 血清および血液を固化する水分散液
JP2017155024A (ja) 2016-03-04 2017-09-07 株式会社ユーグレナ 細胞増殖促進剤
WO2018131721A1 (ja) 2017-01-16 2018-07-19 株式会社Kri 硫酸エステル化修飾セルロースナノファイバーおよびセルロースナノファイバーの製造方法
WO2018230354A1 (ja) 2017-06-16 2018-12-20 東亞合成株式会社 セルロースナノファイバーの製造方法
US20190015564A1 (en) * 2017-07-14 2019-01-17 Soonchunhyang University Industry Academy Cooperation Foundation Adhesion prevention agent comprising injectable thermosensitive wood based-oxidized cellulose nanofiber

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ACS SUSTAINABLE CHEM ENG, vol. 8, 2020, pages 17800 - 17806
CARBOHYDRATE POLYMERS, vol. 197, 2018, pages 349 - 358
CELLULOSE COMMUN, vol. 23, 2016, pages 193 - 199
COCHRANE DATABASE SYST REV
FAN ET AL., BIOMACROMOLECULES, vol. 9, 2008, pages 192 - 198
ISOGAI AKIRA: "Preparation of Bio-nanofibers and Their Applications to Highly Functionalized Materials", JOURNAL OF THE SOCIETY OF FIBER SCIENCE AND TECHNOLOGY, vol. 65, no. 1, 1 January 2009 (2009-01-01), pages 7 - 8, XP055881904, ISSN: 0037-9875 *
KOSAKA ET AL., NATURE MEDICINE LETTERS, vol. 14, no. 4, 2008, pages 437 - 441
LWT-FOOD SCIENCE AND TECHNOLOGY, vol. 86, 2017, pages 318 - 326
MATERIALS SCIENCE AND ENGINEERING C, vol. 102, 2019, pages 12 - 21
See also references of EP4159251A4
SULTANA, T. ET AL.: "TEMPO oxidized nano-cellulose containing thermo-responsive injectable hydrogel for post-surgical peritoneal tissue adhesion prevention", MATERIALS SCIENCE AND ENGINEERING: C, vol. 102, 2019, pages 12 - 21, XP085703209, ISSN: 0928-4931, DOI: 10.1016/j.msec.2019.03.110 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022132201A (ja) * 2021-02-26 2022-09-07 国立大学法人信州大学 表面修飾多糖類ナノ材料、その分散液及び機能性物品
JP7832428B2 (ja) 2021-02-26 2026-03-18 国立大学法人信州大学 表面修飾多糖類ナノ材料、その分散液、機能性物品及び機能性物品の加工法
CN114904053A (zh) * 2022-05-31 2022-08-16 重庆大学 一种基于纤维素纳米晶的抗炎防组织粘连生物涂层及其制备方法和应用

Also Published As

Publication number Publication date
KR20230018490A (ko) 2023-02-07
AR122491A1 (es) 2022-09-14
JP7321610B2 (ja) 2023-08-07
EP4159251A4 (en) 2024-06-19
US20230226098A1 (en) 2023-07-20
TW202210113A (zh) 2022-03-16
JPWO2021246388A1 (https=) 2021-12-09
MX2022015193A (es) 2023-01-04
EP4159251A1 (en) 2023-04-05
BR112022022193A2 (pt) 2022-12-13
CA3189526A1 (en) 2021-12-09
JP2023096193A (ja) 2023-07-06
AU2021284433A1 (en) 2022-12-01
ZA202211627B (en) 2024-02-28
CN115884800A (zh) 2023-03-31

Similar Documents

Publication Publication Date Title
JP6868314B2 (ja) ヒアルロン酸−カルシウム及びポリリシンを含む創傷被覆材及びその製造方法
JP5489999B2 (ja) 外科用ハイドロゲル
JP2023096193A (ja) 分散液及びその製造方法
US11787922B2 (en) Hydrophobically modified chitosan compositions
US8912168B2 (en) Modified starch material of biocompatible hemostasis
CN100398159C (zh) 水溶性纤维素醚化衍生物止血材料
EP3178500B1 (en) Flexible bioresorbable hemostatic packing and stent
JPWO2015099083A1 (ja) 血清および血液を固化する水分散液
JP2004174222A (ja) アルデヒド変性した多糖類を含有している止血用の傷用包帯
JP2752782B2 (ja) 可溶性止血織物
JP2022509912A (ja) 酸化セルロースを含む組成物
Fang et al. Hemoadhican Fiber composite with carbon dots for treating severe hemorrhage and infected wounds
HK40083605A (en) Adhesion-preventing agent and method for preventing adhesion using same
JPH11276572A (ja) ポリ（γ−グルタミン酸）塩複合体からなる医療材料
CN107715167A (zh) 作为骨蜡替代物的壳聚糖基止血糊剂及制备方法
JP2003019194A (ja) ヒアルロン酸とカルボキシメチルセルロースからなる共架橋ゲル組成物
CN114748677A (zh) 一种抗粘连的水凝胶粘合剂及制备方法、应用
RU2833410C1 (ru) Гемостатическое средство
Sarkar et al. Biopolymers in Wound Dressing
KR20250035120A (ko) 겔화능 및 생분해능이 개선된 유착 방지제 및 이의 제조방법
JPH1077571A (ja) 可溶性止血セルロース繊維
Chai et al. Nano-Crosslinking Reinforcement and In-Situ Bubble Regulation Strategy for Constructing Injectable Quaternized Chitosan/Sodium Alginate Hydrogel with Robust Hemostatic Performance
WO2000028978A1 (en) Agents for repairing damaged tissue sites
JPWO2000028978A1 (ja) 組織損傷部位修復剤
JP2000191702A (ja) 成形物の製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21817270

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2022528834

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022022193

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202217067682

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 3189526

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021284433

Country of ref document: AU

Date of ref document: 20210601

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112022022193

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221031

ENP Entry into the national phase

Ref document number: 20227046355

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021817270

Country of ref document: EP

Effective date: 20230102

WWE Wipo information: entry into national phase

Ref document number: 2022134262

Country of ref document: RU

WWW Wipo information: withdrawn in national office

Ref document number: 1020227046355

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2021817270

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2022134262

Country of ref document: RU